Recruiting

New pancreatic cancer treatment for patients who've tried other drugs

Plain-English translation of NCT07823049 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated September 2026 · How we translate trials

Read our Pancreatic Cancer research guide →

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called XNW28012 in people with metastatic pancreatic cancer—cancer that has spread beyond the pancreas—who have already tried two rounds of standard chemotherapy without success. About 226 patients will receive either the new medication or a placebo (a dummy injection) every three weeks, along with supportive care to manage symptoms and side effects. Researchers want to see if this treatment can slow cancer growth and improve survival.

Pancreatic cancer is very difficult to treat, and many patients stop responding to standard chemotherapy. This medication is designed to work in a different way than traditional drugs, and doctors hope it may help people whose cancer has become resistant to earlier treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced pancreatic cancer that has spread (metastatic pancreatic ductal adenocarcinoma), confirmed by a biopsy or cell sample
your cancer has stopped responding to or you could not tolerate two previous standard chemotherapy treatments (gemcitabine and fluorouracil-based therapy)
you are 18 years old or older
you have at least one measurable tumor that can be tracked on imaging scans and has not been treated with radiation or has clearly grown after radiation
your overall health and organ function are adequate enough to receive the treatment, as checked by blood tests and physical exam within 7 days before starting

You likely don't qualify if…

you have had a severe allergic reaction or infusion reaction to similar cancer drugs, especially antibody-drug conjugates or monoclonal antibodies
you have received other cancer treatments too recently (less than 2–4 weeks ago, depending on the type), as you need adequate time between treatments
you have another active cancer elsewhere in your body (except certain skin cancers or early bladder/cervical cancers that have been cured)
you received a live vaccine within the past 4 weeks
you are pregnant or breastfeeding, or if you are a woman of childbearing age and cannot use reliable contraception during the study and for 6 months after treatment ends

What participation looks like

If you qualify, you will be randomly assigned to receive either the new medication or a placebo injection—you and the doctors won't know which—once every 3 weeks. You will visit the clinic for injections and to have blood tests and imaging scans to monitor how your cancer is responding. Throughout the study, you'll also receive supportive care including help managing pain, nutrition, and other symptoms. The study is still recruiting patients, so your commitment will depend on how long the treatment continues and how your cancer responds.

AI-generated summary from trial data · Sep 19, 2026 · Not medical advice

New pancreatic cancer treatment for patients who've tried other drugs

What is this trial?

Do you qualify?

What participation looks like

Trial locations